Develops non-opioid pain management products for acute and chronic pain conditions.
Virpax Pharmaceuticals, Inc., based in Berwyn, Pennsylvania, operates as an innovative pharmaceutical company in the preclinical stages. Specializing in advanced drug-delivery systems and drug-releasing technologies, Virpax focuses on developing non-opioid, non-addictive treatments for pain management and central nervous system disorders. The company's diverse pipeline includes several promising preclinical stage product candidates. These include Epoladerm, a topical nonsteroidal anti-inflammatory treatment designed for chronic osteoarthritis of the knee, and Probudur, an injectable local anesthetic utilizing liposomal gel technology for effective postoperative pain relief.
Among its innovative developments, Virpax Pharmaceuticals is advancing Envelta, a nanotechnology-based intranasal spray engineered to deliver metabolically labile peptide drugs directly into the brain. This underscores the company's commitment to pioneering novel therapeutic approaches that enhance drug efficacy and patient outcomes in challenging neurological conditions. Additionaly, Virpax's pipeline features PES200, AnQlar a potential anti-viral barrier against infections like influenza and SARS-CoV-2 and VRP324, an investigational nasal formulation aimed at improving the delivery of cannabidiol to the brain.
Founded in 2016, Virpax Pharmaceuticals continues to expand its capabilities and influence within the pharmaceutical industry. Through its strategic focus on cutting-edge research and development, the company aims to address critical gaps in pain management and neurological disorders, leveraging scientific innovation to improve the lives of patients worldwide.